<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="viruses-11-00807-t004" orientation="portrait" position="float">
 <object-id pub-id-type="pii">viruses-11-00807-t004_Table 4</object-id>
 <label>Table 4</label>
 <caption>
  <p>Summary of the selected VEEV IAB TrD strain in mice, NHPs, and humans.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"> </th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">BALB/c Mouse</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cynomolgus Macaque</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Humans</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Route of Exposure</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SC (scruff of neck, footpad)
     <break/>Aerosol (whole body)
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aerosol</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aerosol (laboratory exposure)
     <break/>Parenteral (vector-borne, laboratory exposure, vaccine-related)
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Disease and Mortality</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lethal infection after SC and aerosol exposure due to encephalitis even at low challenge doses, with death 5–7 days post-challenge [
     <xref rid="B48-viruses-11-00807" ref-type="bibr">48</xref>,
     <xref rid="B64-viruses-11-00807" ref-type="bibr">64</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Generally non-lethal infection after SC and aerosol exposure at high challenge doses (100% infection after aerosol challenge 1 × 10
     <sup>8</sup> pfu); death uncommon.
     <break/>Increased severity of CNS disease after aerosol challenge [
     <xref rid="B52-viruses-11-00807" ref-type="bibr">52</xref>,
     <xref rid="B64-viruses-11-00807" ref-type="bibr">64</xref>].
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Generally non-lethal infection after SC or aerosol exposure [
     <xref rid="B52-viruses-11-00807" ref-type="bibr">52</xref>] Infection common after exposure to low doses.
     <break/>Encephalitis uncommon (&lt;0.5%); mainly in children/elderly
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Exposure Dose</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LD
     <sub>50</sub> SC ~10 pfu;
     <break/>LD
     <sub>50</sub> aerosol &lt;1 pfu 
     <sup>a</sup>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ID
     <sub>50</sub> unknown
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low infective dose (exposure dose unknown in humans)</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Disease Onset</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24–72 h</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24–48 h</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24–72 h (range 24 h–8 days)</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Signs and Symptoms; Progression of Disease</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nearly 100% mice infected develop disease. Mice infected by the SC route demonstrated initial signs of decreased grooming and ruffled fur 2–3 days after challenge; followed by lethargy, hunched posture, and hind-limb paralysis; death or euthanasia 5–7 days after challenge.
     <break/>Mice infected by aerosol route demonstrated onset of similar signs 2–3 days after challenge, and death or euthanasia 6–7 days after challenge.
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aerosol VEEV TrD challenge results in fever and lethargy within 24–48 h after challenge. Fever resolved by D9. May have mild tremors. Generally NHPs have full recovery.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Self-limiting febrile illness, usually &lt;1 week duration (asthenia may persist 1–2 weeks). Symptoms of high fever, chills, severe headache, back pain, malaise, myalgia, anorexia, nausea, sore throat, fatigue, photophobia, and/or vomiting.
     <break/>Encephalitis uncommon (&lt;1% cases); manifested by decreased sensorium, confusion, gait abnormalities; severe cases with seizures, paralysis, or coma.
     <break/>Most cases recover without neurological sequelae. 
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Clinical Laboratory</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not done.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Viremia observed initially on D1–D2 that resolved by D3–D4
     <break/>Lymphopenia observed early in illness. Increase in WBC observed later in some NHPs [
     <xref rid="B37-viruses-11-00807" ref-type="bibr">37</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Viremia common D1–D4 (range D1–D7 illness) after aerosol and SC challenge. VEEV isolation from pharynx common D1–D4 (range D1–D7) in VEE IAB TrD and VEE IAB Co1938 strains [
     <xref rid="B52-viruses-11-00807" ref-type="bibr">52</xref>]. Lymphopenia common D1–D3 of illness, with improvement after D3 and recovery by D6. Leukopenia may occur D3–D5; resolves by D5–D8 illness [
     <xref rid="B52-viruses-11-00807" ref-type="bibr">52</xref>]. 
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Pathology</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Death due to encephalitis. CNS entry occurs via the olfactory system. Histological lesions present in both neural and extraneural tissues; CNS lesions characterized by necrotizing panencephalitis and myelitis; congestion and minor hemorrhage, damaged endothelial cells, perivascular edema, minimal necrosis and infiltration of a few neutrophils and mononuclear cells (no vasculitis) [
     <xref rid="B48-viruses-11-00807" ref-type="bibr">48</xref>,
     <xref rid="B64-viruses-11-00807" ref-type="bibr">64</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Limited pathology studies in cynomolgus macaques with TrD strain.
     <break/>Intraperitoneal challenge of Rhesus macaques showed histopathology findings initially in lymphoid tissues; lesions in olfactory cortex and thalamus by D6, and in hypothalamus and throughout brain by D8. Predominant lesions of gliosis and multifocal perivascular cuffing composed of lymphocytes. CNS lesions most severe between D14 and D21 post-challenge (observed in 18/20 NHPs). Aerosol challenge rhesus macaques (VEEV-subtype unknown) noted VEEV in nasal mucosa, lungs, cervical/hilar lymph nodes by 18 h, olfactory bulb by 48 h; more severe CNS infection than intraperitoneal challenge (higher CNS viral titers, increased neuronal damage, neuronophagia, and neutrophil infiltration); CNS infection preceded onset of viremia [
     <xref rid="B52-viruses-11-00807" ref-type="bibr">52</xref>,
     <xref rid="B64-viruses-11-00807" ref-type="bibr">64</xref>,
     <xref rid="B65-viruses-11-00807" ref-type="bibr">65</xref>,
     <xref rid="B66-viruses-11-00807" ref-type="bibr">66</xref>].
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CNS pathology available in humans with VEEV IC (see 
     <xref rid="viruses-11-00807-t005" ref-type="table">Table 5</xref>). 
    </td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>D = day; SC = subcutaneous. 
    <sup>a</sup> Starting concentration and all-glass impinger samples for aerosol exposure quantitated by plaque assay to determine titer (pfu/mL); Guyton and Bide formulas used to calculate the inhaled exposure dose per animal.
   </p>
  </fn>
 </table-wrap-foot>
</table-wrap>
